I
Overview
iota Biosciences develops ultra-small, implantable bioelectronic devices that monitor and modulate bodily signals from inside the body. Their neural dust concept uses ultrasound to power these tiny implants and to carry data, enabling millimeter-scale devices implanted with minimal invasiveness. This approach eliminates bulky batteries and wired connections, allowing deep-tissue sensing and precise neuromodulation for real-time, closed-loop therapies. Astellas acquired Iota in 2020 to accelerate clinical development across areas like bladder disorders, autoimmune diseases, cancer, and neurological conditions.
Work here?Claim your company
Simplify's Take
What believers are saying
- Akyva launched recruiting in September 2025 for underactive bladder patients.
- ClinicalTrials.gov updated Akyva on February 9, 2026, showing active development.
- Maharbiz said in April 2026 that iota's technology is novel, working, and incredible.
What critics are saying
- Akyva is only recruiting 15 patients in Australia, exposing slow clinical validation.
- Michel Maharbiz left iota in April 2026, signaling leadership transition risk.
- If Akyva misses 2027 FDA milestones, Astellas could deprioritize or absorb iota.
What makes iota Biosciences unique
- Ultrasound-powered neural dust remains iota's core moat, enabling millimeter-scale implants.
- Astellas acquired iota in 2020, giving it pharma capital and regulatory infrastructure.
- Michael Woods, an MD device leader, now runs urological therapies and commercialization.
Help us improve and share your feedback! Did you find this helpful?